Effects of pseudoephedrine on parameters affecting exercise performance: a meta-analysis by Gheorghiev, Maria D et al.
SYSTEMATIC REVIEW Open Access
Effects of pseudoephedrine on parameters
affecting exercise performance: a meta-
analysis
Maria D Gheorghiev1,4, Farzad Hosseini1, Jason Moran1,3* and Chris E Cooper1,2*
Abstract
Background: Pseudoephedrine (PSE), a sympathomimetic drug, commonly used in nasal decongestants, is
currently banned in sports by the World Anti-Doping Agency (WADA), as its stimulant activity is claimed to
enhance performance. This meta-analysis described the effects of PSE on factors relating to sport performance.
Methods: All included studies were randomised placebo-controlled trials and were conducted in a double blind
crossover fashion. All participants (males and females) were deemed to be healthy. For the primary analysis,
standardised mean difference effect sizes (ES) were calculated for heart rate (HR), time trial (TT) performance, rating
of perceived exertion, blood glucose, and blood lactate.
Results: Across all parameters, effects were trivial with the exception of HR, which showed a small positive increase
in favour of PSE ingestion (ES = 0.43; 95% confidence interval: − 0.01 to 0.88). However, subgroup analyses revealed
important trends. Effect sizes for HR (increase) and TT (quicker) were larger in well-trained (VO2 max (maximal oxygen
consumption) ≥ 65 ml/kg/min) and younger (< 28 years) participants, for shorter (< 25 mins) bouts of exercise and
when PSE was administered less than 90 min prior to performance. There was evidence of a dose-response effect for
TT and HR with larger doses (> 170 mg) resulting in small (ES = − 0.24) and moderate (ES = 0.85) effect sizes respectively
for these variables.
Conclusions: We conclude, however, that the performance benefit of pseudoephedrine is marginal and likely to be less
than that obtained from permitted stimulants such as caffeine.
Keywords: Performance-enhancing drugs, Anti-doping, Training, Sport, Pseudoephedrine, Stimulant
Key points
 Pseudoephedrine use exerts an effect on heart rate,
but there is no effect on time trial performance,
perceived effort, or biochemical markers (blood
glucose and blood lactate).
 Effects could be more apparent in just those athletes
of most concern to anti-doping agencies: younger
and well-trained athletes.
 Any performance benefit of pseudoephedrine is
marginal and certainly less than that obtained
through permitted stimulants such as caffeine
Background
Pseudoephedrine (PSE) is a sympathomimetic amine
derived from the plant genus Ephedra, most commonly
used at therapeutic levels (60 mg) to relieve nasal conges-
tion. The principal mechanism of action of PSE relies on
the indirect stimulation of peripheral α1-adrenergic recep-
tors, although it also has some ability to stimulate cardiac
β receptors. This causes vasoconstriction at the level of
the nasal mucosa, therefore reducing the blood flow to the
nasal cavity and decreasing inflammation [1]. Despite be-
ing the optimal drug for this condition in many countries,
access to PSE is restricted as it is a precursor material for
the illegal manufacture of amphetamine. Instead, the less
effective phenylephrine is favoured [2].
Due to its similarity in structure with ephedrine and
other central nervous system stimulants, there has been
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speculation that PSE may also exert ergogenic effects. Pre-
viously reviewed by Trinh et al. [3], these effects include
increased systolic and diastolic blood pressure and heart
rate, vasoconstriction in the cutaneous vessels, vasodila-
tion in the skeletal muscle, and breakdown of glycogen in
the liver and muscle. Increased glycogenolysis could lead
to increased glucose supply when it is limiting in exercise,
whereas the proposed inotropic and chronotropic effects
on the heart could raise cardiac output, promoting blood
flow to working muscle and potentially improving per-
formance [4, 5]. Regardless of the theoretical advantages
of PSE, the results of studies to document its efficacy as
an ergogenic agent are equivocal. Many studies have
found little, or no, ergogenic effect [6–12], although some
researchers reported larger-than-therapeutic doses to be
effective in enhancing performance [13–15].
This inconsistency in research findings is reflected in
the variability in PSE’s regulation by anti-doping
agencies and other sporting bodies. The International
Olympic Committee banned PSE until 2004 when the
World Anti-Doping Agency (WADA) removed it from
the prohibited list. In 2010, after a monitoring program
that suggested increased use by athletes following the
lifting of the ban, it was banned again. However, pseudo-
ephedrine is not banned in professional sports that do
not follow the WADA prohibited list, one example being
ice hockey, in which it is used extensively. Even one pill
a day used as a decongestant can trigger a positive drug
test, and this can lead to unfortunate consequences such
as the banning of Swedish National Hockey League
player Nicklas Backstrom from the gold medal game of
the Sochi 2014 Winter Olympics.
A recent systematic review by Trinh et al. [3] used quali-
tative analysis to suggest that only higher doses of PSE are
likely to enhance performance. The authors argued the
limited studies available were too heterogeneous to per-
form a quantitative meta-analysis to supplement their find-
ings. We performed a new review, finding seven additional
articles not included by Trinh et al. [3]. The inclusion of
these articles made a quantitative analysis possible, not just
in terms of PSE’s potential effect on performance, but also
on physiological (heart rate [HR]), biochemical (blood glu-
cose [GLU], blood lactate [LAC]), and psychological (RPE)
markers that could inform on the proposed mechanism of
action. Our analysis provides quantitative support for the
qualitative assertion by Trinh et al. [3] that therapeutic
doses of PSE do not affect performance. However, we also
question their view that supratherapeutic doses of PSE
induce an ergogenic effect.
Methods
This review complies with the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
statement [16]. An extensive literature search was carried
out prior to statistical analyses using a random-effects
model.
Search and selection strategy
Figure 1 outlines the search process. A search of the
PubMed database took place in October and November
2015. After the identification of 13 eligible studies, a
citation track was conducted and three more articles
were found. This was combined with a search of articles’
references lists, focusing on those which had cited the
original 13 articles identified. This was further supple-
mented by Google Scholar searches in November 2015
and August 2017. As of February 2018, no new relevant
references were found using citation searches of the final
16 articles selected. Terms included in the search were
‘pseudoephedrine’ in combination with ‘heart rate’, ‘time
trial’, ‘athletes’, ‘cycling’, ‘running’, ‘exercise’, ‘ergogenic’,
‘sport’, and ‘doping’. These terms were searched for in the
title and the abstract of studies.
Study selection criteria
Only articles investigating the effect of PSE on exercise per-
formance were selected. Authors must have provided
enough information to derive means and standard devia-
tions for performance tests. Studies must have used PSE as
the only substance in the intervention, and they were
excluded if the substance was not specifically being investi-
gated for its ergogenic effect [17]. Also excluded were
studies investigating the effects of PSE on strength and
neuromuscular coordination because data were incompar-
able with included articles [10, 18]. Studies that investigated
other substances were included if participants were not ad-
ministered both substances simultaneously [7, 12, 19]. All
studies were randomised placebo-controlled trials and were
conducted in a double blind crossover fashion. All partici-
pants (males and females) were deemed to be healthy. Each
protocol of the 16 studies included in this meta-analysis re-
quired the participants to abstain from use of stimulants
before the trials and some studies had a pre-planned meal.
Data extraction
To estimate the effect of PSE on performance, data for the
following variables were extracted from the gathered
articles where available: HR, GLU, LAC, time trial (TT)
performance, and RPE. Table 1 shows the characteristics of
the 16 studies included in the meta-analysis. Eleven of
these measured HR [7, 8, 11, 13–15, 19–23], 5 measured
GLU [6, 7, 14, 15, 23], 6 measured LAC [7, 13–15, 19, 24],
9 measured TT [9, 14, 15, 19, 21–25], and 5 measured RPE
[8, 12, 15, 22, 23]. Where data were presented only in
figures [7, 24], authors were directly contacted for the raw
data. If these were not available, the figures were enlarged
and values were calculated using a ruler [26].
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Statistical analysis
The meta-analysis was carried out using the RevMan [27]
software. The inverse-variance random-effects model for
meta-analyses was used as it proportionately weights stud-
ies based on the magnitude of their standard errors [28]
and accounts for heterogeneity across trials [29]. Effect
sizes are presented as the standardised mean difference
with 95% confidence intervals and were evaluated with the
scale of Hopkins et al. [30]: < 0.2 = trivial; 0.2–0.59 = small,
0.6–1.19 =moderate, 1.2–1.99 = large, 2.0–3.99 = very
large, ≥ 4.0 = extremely large. To account for the crossover
design of the included studies, data for experimental and
placebo conditions were analysed in the manner of a paral-
lel group trial [28]. This method can result in wider than
normal confidence intervals and underweighting of studies
[28] though the short half-life of PSE (≤ 8 h [31]), coupled
with more extensive washout periods, reduces the
confounding impact of these factors. Study heterogeneity is
represented by the I2 statistic which is the variation of
effects that could be attributed to differences across studies
rather than to chance. Low, moderate, and high
heterogeneity correspond to I2 values of 25%, 50%, and
75% respectively [32].
Results
The 16 analysed studies included 168 participants. Most
(81%) had only male participants while two (12.5%) had
only female participants. One (6.5%) study included both
sexes. Mean ages ranged from 18 to 38 years, with only
one study [22] allowing participants up to 60 years. Par-
ticipants were either competitive athletes or volunteers
with an interest in sport.
Primary effects
The pooled mean estimates for the effect of PSE on HR,
TT, RPE, GLU, and LAC are shown in Table 2 and
Figs. 2, 3, 4, 5, and 6. Effects were generally positively or
negatively trivial across parameters with the exception of
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HR which showed a small positive effect in favour of
PSE ingestion.
Effects in subgroups
Subgroups, chosen by a median split, revealed important
trends (Table 3). Effect sizes on HR and TT tended to be
larger in well-trained (≥ 65 ml/kg/min) and younger (<
28 years) participants. Effects were also larger for shorter
(< 25 min) bouts of exercise and when PSE was adminis-
tered less than 90 min prior to performance. For longer
duration exercise (≥ 90 mins), small effects were also ap-
parent for RPE. There was evidence of a dose-response for
TT and HR with larger doses (> 170 mg) resulting in small
and moderate effect sizes respectively for these variables.
Discussion
Our results quantitatively demonstrate that PSE causes a
small increase in HR during exercise. In terms of the other
parameters studied, there were trivial improvements in
time trial performance, a trivial reduction in RPE and triv-
ial decreases in GLU and LAC levels during exercise. It
could be argued that these equivocal findings suggest a
meta-analysis would better wait until a larger number of
studies have been performed, thus leading to a more
robust conclusion. However, the intriguing subgroup
analyses argue against this. Effect sizes tended to be larger
in just those athletes of most concern to anti-doping agen-
cies (younger and well-trained athletes). They also suggest
an optimal time and activity to take the drug, indicating
PSE is most effectively administered less than 90 min
before a short bout of exercise of less than 25 min. Of
particular concern is that our subgroup analysis confirms
the qualitative review [3] that larger doses (> 170 mg) are
likely to be the most effective in improving performance.
However, this was accompanied by a larger effect on in-
creasing HR. A recent study looking at neuromuscular
performance effects using these more effective higher PSE
doses (180 mg) noted adverse side effects such as tachy-
cardia and heart palpitations 24 h after exercise [18]. This
suggests it will be increasingly difficult to get ethical ap-
proval to test the most effective doses of PSE, making it
important to carry out the most complete analysis of the
studies that have already been performed.
Comparison to previous systematic reviews
The initial search for our systematic review was carried
out at approximately the same time as that of the recent
systematic review by Trinh et al. [3] and subsequent
searches uncovered no additional studies of interest. How-
ever, the studies deemed appropriate for detailed analysis
were different. Whilst our search confirmed and agreed
with the many of the studies chosen by Trinh et al. [3], we
included some additional publications. As our enhanced
sample enabled the meta-analysis that Trinh et al., [3] felt
not to be justified, we feel it is important to justify the
rationale for the additional papers chosen.
Both reviews focused on the performance effects of PSE
using a randomised-controlled trial approach. As our
study was designed to enable a meta-analysis, it was
restricted to sports performances that had a time trial
component and/or included quantitative measures that
could inform potential underlying mechanisms (such as
Table 2 Effect sizes and descriptors for parameters studied
Parameter HR TT RPE GLU LAC
Effect size (95% confidence interval) 0.43 (− 0.01, 0.88) − 0.17 (− 0.46, 0.13) −0.08 (− 0.47, 0.30) −0.19 (− 0.66, 0.27) −0.15 (− 0.69, 0.38)
Effect size descriptor Small increase Trivial decrease Trivial decrease Trivial decrease Trivial decrease
HR, heart rate; TT, time trial; RPE, rate of perceived exertion; GLU, blood glucose; LAC, blood lactate
Fig. 2 Forest plot for effects of PSE on HR with 95% confidence intervals, HR, heart rate; PSE, pseudoephedrine; PLA, placebo; SD, standard
deviation; Std., standardised; IV, instrumental variables; CI, confidence interval. Positive effect sizes represent an increase in HR due to PSE.
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LAC, GLU, HR, and RPE). This biased our search to
include only those studies that focused on sports events
with an aerobic component. This approach ruled out one
article included by Trinh et al. [3], a study by Chu et al.
[10] showing that a moderate dose (120 mg) of PSE did
not alter muscle action strength or anaerobic power. It
also ruled out a recent study published after both system-
atic searches. In 2015, Pallarés et al. [18] measured bench
press and full squat exercise performance against four in-
cremental loads (25%, 50%, 75%, and 90% one repetition
maximum). No effects were seen except in the highest
dose studied (180 mg) where PSE seemingly increased
lower body muscle contraction velocity.
Trinh et al. [3] conducted their analysis on only 10 stud-
ies and concluded that the data were insufficient and too
variable to enable a meta-analysis. We feel that, at least in
part, this conclusion is based on the combination of a
flawed search strategy and an overly restrictive view of
which articles to select from that search. We found seven
additional papers omitted by Trinh et al. [3], all of which
used randomised placebo designs to assess the effect of
PSE on aspects of performance. On this basis, these studies
could, in principle, fit the criteria used by Trinh et al. [3].
These articles are highlighted in Table 1 and owing to their
importance to our final meta-analysis, it is crucial that we
justify their inclusion individually (see discussion in
Table 4).
Given that Trinh et al. [3] only included 10 articles in
their final qualitative synthesis, the exclusion of seven
relevant studies represents a significant fraction of the
available literature. Crucially, all seven studies excluded
showed no effect of PSE on performance. This may not be
related to a dose effect as three studies [6, 8, 22] were at
low (clinically approved) doses and four were at
supratherapeutic doses [19, 20, 23, 24]. It is possible that
excluding such a large fraction of data biased the final
conclusion of that review, particularly the comment that
“qualitative analysis showed overall positive results in
favour of PSE over placebo for PSE doses ≥180 mg or
2.5 mg/kg”. Of the 10 studies included by Trinh et al.
[3], all three high dose studies showed an ergogenic
effect, and all seven lower dose studies showed PSE to
be ineffective, making their conclusion reasonable. How-
ever, adding the seven omitted studies would signifi-
cantly weaken this argument as only 3 out of 7 high
dose studies demonstrate a positive effect of PSE. There-
fore, although there is clearly an increase in HR during
exercise due to PSE, we are more equivocal than Trinh
et al. [3] about the drug’s positive ergogenic effects, even
at high doses. Including these new articles does,
Fig. 3 Forest plot for effects of PSE on TT with 95% confidence intervals, PSE, pseudoephedrine; PLA, placebo; SD, standard deviation; Std.,
standardised; IV, instrumental variables; CI, confidence interval. Negative effect sizes represent a shorter TT performance due to PSE.
Fig. 4 Forest plot for effects of PSE on RPE with 95% confidence intervals. RPE, rating of perceived exertion; PSE, pseudoephedrine; PLA, placebo;
SD, standard deviation; Std., standardised; IV, instrumental variables; CI, confidence interval. Positive effect sizes represent an increased RPE due
to PSE.
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however, strongly favour the conclusion that when taken
at clinically recommended doses, PSE has only a very
minor effect on HR and no ergogenic effect in terms of
performance.
Relevance for putative mechanism of any performance
benefit
Our analysis suggests that only at high doses does PSE
have the potential to enhance sports performance. It also
sheds some light on to the possible mechanism that could
be operating. A previous meta-analysis demonstrated that,
at rest, PSE caused a statistically significant small increase
in systolic blood pressure (1 mmHg) and HR (3 beats/
min), although diastolic blood pressure did not change.
We found 11 studies reporting HR changes following PSE
ingestion during exercise. Our data showed that this mean
HR increase is maintained during exercise with the largest
increase being 13 beats/min [20]. The subgroup analyses
showed that the biggest effect sizes were seen at high
doses and in athletes with high maximal oxygen uptake
(VO2 max). Three individual studies showed a perform-
ance effect [13–15]. Gill et al. [13] showed that HR in-
creased significantly from 166 to 175 beats/min, and
Hodges et al. [14] demonstrated a non-significant increase
from 185 to 190 beats/min. Similarly, Pritchard-Peschek
et al. [15] also reported a non-significant increase was
from 176 to 180 beats/min. Given that studies that
showed no performance increase showed at least as large
and as significant HR increases during exercise, it seems
unlikely that—in and of itself—changes in HR underpin
any performance enhancement.
In relation to RPE, GLU, and LAC levels in exercise, a
lack of data is more challenging to overcome with only be-
tween five and seven studies reporting sufficient informa-
tion. We observed a small, trivial decrease in all of these
parameters. However, it is worth exploring the individual
studies, as the statistical power of pairing individuals in a
crossover study is lost during a meta-analysis.
For RPE, none of the five studies included showed
meaningful differences between PSE and placebo [8, 12,
15, 22, 23]. An additional study did not report values,
but did state that there were no significant differences
[7]. Glucose levels were not significantly different in four
of the five studies included in the meta-analysis [6, 7, 14,
23]. An additional study, not part of the analysis as it re-
ported no values, again stated a lack of any PSE effect
on GLU [25]. However, one study did report increased
GLU levels post exercise following PSE treatment [15].
This was one of the few studies that also showed a per-
formance effect (decreased time in cycling TT). Interest-
ingly in this case, it was the pre-exercise GLU level that
correlated with the increased performance in the cycling
time trial. Lactate levels did not significantly change in
five of the seven studies included in the meta-analysis [7,
13–15, 23]. However, they did significantly decrease in
two studies [19, 24]. In one study, LAC levels were not
Fig. 5 Forest plot for effects of PSE on GLU with 95% confidence intervals. GLU, blood glucose; PSE, pseudoephedrine; PLA, placebo; SD, standard
deviation; Std., standardised; IV, instrumental variables; CI, confidence interval. Positive effect sizes represent an increase in GLU due to PSE
Fig. 6 Forest plot for effects of PSE on LAC with 95% confidence intervals.LAC: Blood lactate; PSE, pseudoephedrine; PLA, placebo; SD, standard
deviation; Std., standardised; IV, instrumental variables; CI, confidence interval. Positive effect sizes represent an increase in LAC due to PSE
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reported, the authors nonetheless stating there was no
significant change [25].
Given that only 3 of the 16 studies included in our ana-
lysis showed a performance benefit, it is worth exploring
in detail, which secondary parameters changed in these
studies to see if this can inform mechanism. Gill et al. [13]
measured an increase in maximum torque in an isometric
knee extension and an improvement in peak power during
maximal cycle performance in 22 healthy male volunteers.
In terms of lung function, small, but significant, increases
were seen in forced vital capacity (FVC) and forced ex-
pired volume in 1 s (FEV) following ingestion of PSE.
These are consistent with the well-characterised role of
PSE in stimulating the sympathetic nervous system and
acting as a bronchodilator [33]. This is unlikely to explain
the effect on peak power observed here, nor is a small in-
crease in FVC and FEV likely to improve sports perform-
ance in endurance events given the lack of consistent
ergogenic effect of drugs that are far more effective in
increasing lung function such as salbutamol [34].
Hodges et al. [14] found that PSE significantly
decreased time to completion of a 1500 m time trial in 7
healthy male subjects. However, no other measured pa-
rameters (HR, LAC, GLU, arterial O2 partial pressure,
arterial carbon dioxide partial pressure and arterial
oxygen saturation) were significantly altered.
Pritchard-Peschek et al. [15] reported a significant im-
provement in a cycling TT performance following PSE
in six trained male cyclists and triathletes. As previously
noted, this study reported increased post exercise GLU
levels following PSE treatment. No significant PSE effect
was found on LAC, blood pH, substrate oxidation, RPE,
or HR. PSE did significantly increase plasma norepin-
ephrine concentrations, an expected outcome for a drug
that has indirect agonist activity on cardiac β receptors
and peripheral α1 receptors, through release of norepin-
ephrine from the cytoplasmic pool [14]. However, the
validity of any ergogenic effects of this increased β re-
ceptor activity is undermined by the two subsequent
similar studies from this group, which used larger sam-
ple sizes (n = 10) and showed no performance benefit
despite an increase in plasma norepinephrine [24, 25].
Readily available drugs used as decongestants that are
not banned by WADA such as phenylephrine act dir-
ectly on peripheral α receptors and have limited ability
to cross the blood-brain barrier and/or act as a central
stimulant [2]. PSE is more lipid soluble and is therefore
more accessible to the central nervous system. Conse-
quently, it can, in principle, act as both a peripheral or
central stimulant. However, the biochemical, physio-
logical, and psychological data in our systematic review
and meta-analysis fail to give a consistent explanation to
underpin a possible ergogenic mechanism. Heart rate
did increase, however, in most studies there was no
accompanying performance benefit; indeed in some
studies which showed a performance benefit, there is no
significant heart rate change. A few studies show plasma
metabolite changes (GLU/LAC) that might suggest
Table 3 Subgroup analysis
HR TT RPE GLU LAC
Subgroup Median split Effect size Groups N Effect size Groups N Effect size Groups N Effect size Groups N Effect
size
Groups N
PSE dose > 170 mg 0.85 6 49 − 0.24 6 54 0.00 2 16 − 0.08 3 24 − 0.09 5 56
≤ 170 mg 0.11 5 48 − 0.06 4 37 − 0.11 3 37 − 0.41 2 13 − 0.51 1 7
Exercise
duration
≥ 25 mins 0.38 6 49 − 0.08 7 61 0.02 3 23 − 0.08 3 24 − 0.10 4 34
< 25 mins 0.55 5 48 − 0.34 3 30 − 0.16 2 30 − 0.41 2 13 − 0.18 2 29
Age > 28 years 0.32 7 60 − 0.12 6 51 0.02 3 23 − 0.08 3 24 − 0.10 4 34
< 28 years 0.77 4 37 − 0.22 4 40 − 0.16 2 30 − 0.41 2 13 − 0.18 2 29
VO2 max ≥ 65 ml/kg/
min
0.69 4 33 − 0.40 4 35 − 0.31 1 10 − 0.18 3 25 − 0.52 2 15
< 65 ml/kg/
min
0.07 4 37 − 0.10 3 26 − 0.06 3 36 − 0.27 1 6 0.05 3 26
Washout
period
(days)
≥ 7 days 0.65 5 45 − 0.19 5 50 − 0.16 2 30 − 0.07 3 21 0.00 4 47
< 7 days 0.31 6 52 − 0.14 5 41 0.02 3 23 − 0.36 2 16 − 0.51 2 16
Pre-exercise
ingestion time
≥ 90 min 0.41 6 57 − 0.10 6 58 − 0.31 1 10 − 0.18 3 25 0.03 3 25
< 90 min 0.54 5 40 − 0.34 3 26 − 0.06 3 36 − 0.21 2 12 − 0.30 3 38
Mode of
exercise
Cycling 0.77 6 52 − 0.09 6 54 − 0.04 3 36 − 0.36 2 16 0.00 4 48
Running 0.18 5 45 − 0.16 2 20 − 0.36 1 10 − 0.07 3 21 − 0.52 2 15
PSE, pseudoephedrine; HR, heart rate; RPE, rate of perceived exertion; TT, time trial; GLU, blood glucose; LAC, blood lactate; min, minute(s); VO2max, maximum
oxygen uptake
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Table 4 Characteristics of studies included in this meta-analysis that were not included in Trinh et al. [3] systematic review
Authors Title of study Rationale for inclusion in the meta-analysis
Bright et al.
[6]
“Selected cardiac and metabolic responses
to pseudoephedrine with exercise”
This paper studied the cardiac and metabolic responses to pseudoephedrine
with exercise. As GLU after exercise was measured (a non-significant small
decrease was seen), it was included in our study. The relevant performance
measure was ‘time to reach 85% of maximum HR’ during submaximal exercise,
with no effect being seen. The inclusion criteria of Trinh et al. accounted for “any
enhancement in sport above baseline such as timing, strength, time to fatigue
and/or respiratory enhancement”. Although it did not fit our time trial criteria, it
is at least arguable that time to reach 85% of maximum HR fits those of
Trinh et al.
Clemons and
Crosby [8]
“Cardiopulmonary and subjective effects of a
60 mg dose of pseudoephedrine on graded
treadmill exercise”
This evaluated the cardiopulmonary and subjective effects of a 60 mg dose of
PSE on graded treadmill running. The RPE and HR data recorded during exercise
were included in our meta-analysis. However, the time to exhaustion was not, as
it was a graded exercise test rather than a time trial. Despite this, it would seem
that time to fatigue on a treadmill would fit well with the Trinh et al. criteria, so
it was not clear why they did not discuss this research.
Mouatt [23] “The physiological effects of pseudoephedrine
on endurance cycling”
This study looked at the effects of high dose (2.5 mg/kg ≅ 184 mg total) PSE on
endurance cycling. This comprehensive randomised controlled trial was included
in our analysis as it measured HR, GLU, RPE and TT duration. A difficult study to
find owing to it only being published as an MSc. thesis, it is freely and readily
available in open access form via standard search engines (Google etc.).
Nevertheless, as a research thesis from a well-recognised university (Massey),
supervised by a well-published author in the sports and exercise science field
(Toby Mündel), we feel it is appropriate to add to our analysis.
Betteridge
et al. [20]
“The effect of pseudoephedrine on self-paced
endurance cycling performance”
This used a randomised controlled study design to measure HR, GLU, LAC, RPE,
and TT duration after a high dose PSE. Heart rate and TT were included in our
meta-analysis; however, changes in GLU and LAC values could not be used as
they were not reported in sufficient detail. The European Journal of Sports
Science is the official journal of the European College of Sports Science, but was
not listed in Medline until 2013 so the search strategy of Trinh et al. would not
have uncovered it as their search strategy excluded sports and exercise science
databases. Trinh et al.’s criteria also did not include citation or reference searches
of the final selected papers, which might have rectified this omission as the
relevant article was commented on in the discussion of one of the studies [25]
that was cited by Trinh et al.
Gradidge
et al. [22]
“Effect of a therapeutic dose of pseudoephedrine
on swimmers’ performance”
This paper explored the effect of a low dose of PSE on swim performance (TT,
RPE, and HR data were included in our analysis). This double blind randomised
controlled trial was published in the South African Journal of Sports Medicine,
which is absent from the search database used by Trinh et al. [3].
Pritchard-
Peschek [24]
“Pseudoephedrine and preexercise feeding:
influence on performance”
An apparent inconsistency occurred in the selection of studies from Pritchard-
Peschek and collaborators between ourselves and Trinh et al. [3]. Between 2010
and 2014, this group published three randomised controlled trials on PSE and
exercise performance. All included TT data and so were included in our
meta-analysis. However, Trinh et al., only included the papers published in 2010
[15] and 2014 [25], despite the 2013 paper being published in Medicine and
Science in Sports and Exercise and hence readily accessible by Medline. Their
2013 paper [24] had a similar protocol to those in 2010 and 2014 [25], but with
the addition of a pre-ingestion meal group. However, this additional group could
be easily removed for consistency with the other two studies and so was
included in our analysis.
Spence et al.
[19]
“A comparison of caffeine versus pseudoephedrine
on cycling time-trial performance”
This paper was analysed by Trinh et al., but specifically excluded from their
analysis. It compared caffeine and PSE in cycling time trial performance. Trinh
et al. excluded the study as they stated it “focuses on differences between effects
of caffeine and PSE”. However, in their inclusion criteria, they note that “studies
that looked at other substances were included if athletes were not administered
both substances simultaneously”. This article outlined three experimental arms
(caffeine, PSE, and placebo) in a cross-over study with adequate wash out periods
between trials. It is true that the authors focus on the differences between
caffeine and PSE in their discussion, but they give full statistics (means, standard
deviations, and effect sizes) for a comparison between PSE and placebo. In light
of this, by their own criteria, we feel that Trinh et al. should not have excluded
this study.
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improved substrate or oxygen utilisation. However, other
studies show no metabolite changes even when there is a
performance benefit. Unlike other WADA banned stimu-
lants such as amphetamines [35], perception of effort
(RPE) is completely unchanged by PSE at low or high
doses, irrespective of any performance benefit.
Rationale for WADA listing pseudoephedrine as a
prohibited doping substance
The WADA Prohibited List may include any substance
that satisfies any two of the following three criteria: (i) it
has the potential to enhance or enhances sport perform-
ance; (ii) it represents an actual or potential health risk
to the athlete; (iii) it violates the spirit of sport. Appar-
ently, PSE fulfilled these criteria and was banned until
2004, did not fulfil them between 2004 and 2010 (when
it was removed from the banned list), and then fulfilled
them again after 2010 (when it returned to the banned
list). Currently, PSE is only banned in competition. A
doping offence is committed if an athlete has a urine
PSE concentration of greater than 150 μg/ml. Even given
the biological variability of single point measurements,
this level is high enough that it should not be possible to
produce a positive urine test if an athlete discontinues a
therapeutic dose of PSE more than 24 h before competi-
tion. However, it is possible, though not guaranteed, to
exceed these levels within 24 h of taking PSE at the
normal therapeutic dose [9], and it is impossible not to
exceed them when on a supratherapeutic dose [24].
WADA monitored PSE use in doping samples when it
was not banned from 2004 to 2009. WADA’s case for
reintroducing the PSE ban in 2010 was made in a Q and A
statement published as part of the 2010 prohibited list [36]:
“Results of the Monitoring Program over the past five
years have shown a sustained increase in samples contain-
ing pseudoephedrine. The program indicated clear abuse
of this substance with high concentrations in a number of
sports and regions. In addition, available literature shows
scientific evidence of the performance-enhancing effects
of pseudoephedrine beyond certain doses.”
Some increase in PSE use would be expected when the
ban was lifted given that the best drug to treat nasal
decongestion in competition was now freely available to
athletes without the threat of sanction. Presumably, the
geographic and sport-specific nature of the increase
argued against this more benign interpretation. An
additional concern, not specifically noted by WADA, but
stated by some anti-doping researchers, is that one of
PSE’s minor metabolites, norpseudoephedrine (cathine),
was on the banned list during this period. Athletes could
therefore claim a failed cathine doping result was a conse-
quence of taking the now permitted PSE. PSE use would,
therefore, mask cathine abuse [37].
However, our systematic review does question WADA’s
statement that “available literature shows scientific
evidence of the performance-enhancing effects of pseudo-
ephedrine beyond certain doses.” A research article would
need to have been published between 2004 and 2009 to
inform this change of policy. In this period, our search
uncovered three studies reporting no performance effect
[7, 14, 23] and only one coming to the contrary view [14].
That study was published in 2006 and is the only paper
WADA cite in the 2004–2009 period showing a perform-
ance benefit in justification of their decision [38]. It
showed a performance benefit based on only six UK
college 1500 m runners, the fastest running over 4:15 min
for the distance. The International Association of Athletics
Federations (IAAF) qualifying standard for this event in
the 2016 Olympics was 3:36 min, making this subject
group far from elite. Given that PSE is not banned out of
competition, a WADA-approved study in elite athletes
would be beneficial to support the current policy.
Given the difficulty of taking measurements in elite ath-
letes, it is possible that WADA treat the systematic abuse
of a drug by elite athletes as partial evidence for its efficacy
in that subject group. The use of a higher than necessary
dose of a medicine (or even the use at all of a medicine
where there is no clinical need) is also considered to be
against the “spirit of sport”. A similar rationale was
presumably used for the more infamous 2016 banning of
the cardiac drug meldonium once the extremely wide-
spread use of it amongst Eastern European athletes became
known [39], despite the poor evidence base for its
performance-enhancing effect. In the case of PSE, there is
the added concern, that in some countries, to get access to
the higher doses, athletes need to circumvent government
regulations designed to combat the production of illegal
recreational drugs [2].
Conclusions
In contrast to a previous systematic review [3], our analysis
has shown that any performance benefit of PSE is marginal
at best, and certainly less than the well-characterised per-
mitted stimulant caffeine [40]. However, a small perform-
ance benefit at high doses in elite athletes still cannot be
completely ruled out at present.
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